Sophia Genetics announced that it has expanded its work with CHU de Nimes, a regional and university hospital located in the South of France. The hospital system will use the SOPHiA DDM Platform to progress its pharmacogenomics research.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SOPH:
- Sophia Genetics initiated with an Outperform at RBC Capital
- Sophia Genetics expands relationship with largest health center in Italy
- SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023
- Sophia Genetics sees 2023 revenue growth at or above 30%, consensus $62.08M
- Sophia Genetics reports Q3 EPS (21c), consensus (31c)
